

**PATENT**  
Attorney Docket No. PTK-227

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Vaidyanathan et al. CONFIRMATION NO.: Not Yet Assigned  
SERIAL NO.: Not Yet Assigned GROUP NO.: Not Yet Assigned  
FILING DATE: Herewith EXAMINER: Not Yet Assigned  
TITLE: Web Handling Cylinder with Modulated Tension Loss

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the listed references are enclosed.

**REMARKS**

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
  - the requisite Statement is below, **OR**
  - the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or

(3) after the mailing date of a **final action or notice of allowance** but before the payment of the issue fee, AND

the requisite Statement is below, AND

the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.


#### STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or

2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

Respectfully submitted,

  
\_\_\_\_\_  
Steven J. Frank  
Attorney for Applicant(s)  
Testa, Hurwitz, & Thibeault, LLP  
High Street Tower  
125 High Street  
Boston, Massachusetts 02110

Date: July 31, 2003  
Reg. No. 33,497

Tel. No.: (617) 310-8108  
Fax No.: (617) 248-7100

2659962

|   |  |   |  |
|---|--|---|--|
| <b>FORM PTO - 1449</b><br><br><b>INFORMATION DISCLOSURE STATEMENT</b> |  | ATTORNEY DOCKET NO.: PTK-227<br><br>APPLICANT(S): Vaidyanathan et al.<br><br>SERIAL NO.: Not yet assigned<br><br>FILING DATE: Herewith    GROUP: Not yet assigned |  |
|---|--|---|--|

**U.S. PATENT DOCUMENTS**

| EXAM.<br>INIT. |     | DOCUMENT<br>NUMBER | DATE     | NAME                | CLASS | SUB<br>CLASS | FILING DATE IF<br>APPROPRIATE |
|----------------|-----|--------------------|----------|---------------------|-------|--------------|-------------------------------|
|                | A1  | 2001/0006029       | 4/5/01   | Ogawa et al.        |       |              |                               |
|                | A2  | 3,854,329          | 12/17/74 | Jones               |       |              |                               |
|                | A3  | 3,982,710          | 9/28/76  | Teumer              |       |              |                               |
|                | A4  | 4,473,009          | 9/25/84  | Morgan              |       |              |                               |
|                | A5  | 5,024,156          | 6/18/91  | Hank et al.         |       |              |                               |
|                | A6  | 5,130,744          | 7/14/92  | Hisada              |       |              |                               |
|                | A7  | 5,470,005          | 11/28/95 | King et al.         |       |              |                               |
|                | A8  | 5,521,844          | 5/28/96  | Karis               |       |              |                               |
|                | A9  | 5,602,747          | 2/11/97  | Rajala              |       |              |                               |
|                | A10 | 5,712,489          | 1/27/98  | Elvidge et al.      |       |              |                               |
|                | A11 | 5,727,749          | 3/17/98  | Pensavecchia et al. |       |              |                               |
|                | A12 | 5,757,641          | 5/26/98  | Minto               |       |              |                               |
|                | A13 | 5,878,933          | 3/9/99   | Laughery            |       |              |                               |
|                | A14 | 5,944,958          | 8/31/99  | Svanqvist           |       |              |                               |
|                | A15 | 5,992,789          | 11/30/99 | Lamothe             |       |              |                               |
|                | A16 | 6,026,747          | 2/22/00  | Carme et al.        |       |              |                               |
|                | A17 | 6,106,177          | 8/22/00  | Siegl et al.        |       |              |                               |
|                | A18 | 6,168,108 B1       | 1/2/01   | Morley              |       |              |                               |
|                | A19 | 6,176,410 B1       | 1/23/01  | Ueda et al.         |       |              |                               |
|                | A20 | 6,250,220 B1       | 6/26/01  | Sainio et al.       |       |              |                               |
|                | A21 | -6,293,031 B1      | 9/25/01  | Ringbom et al.      |       |              |                               |
|                | A22 | 6,314,333 B1       | 11/6/01  | Rajala et al.       |       |              |                               |
|                | A23 | 6,325,322 B1       | 12/4/01  | Lewis               |       |              |                               |

**EXAMINER****DATE CONSIDERED**